Pfizer Inc. is reorganizing the company into three businesses: a science-based Innovative Medicines business which will include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business and a Consumer Healthcare business. These changes will take effect at the beginning of Pfizer’s 2019 fiscal year.  “This new structure represents a natural evolution of these businesses given the ongoing strength o...